Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
CL

NASDAQ · CLDX

Celldex Therapeutics, Inc.

Healthcare · Biotechnology

$30.10

Up+$0.21 (+0.70%)

Updated Oct 31, 2026, 11:33 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.86B
P/E ratio
-9.3
Dividend yield
0.00%
52-week range
$27.47 – $45.14
Volume
870.78K
Avg. volume
937.83K

Price performance · CLDX

CLDX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

CLDX closed at $30.10 after 21 trading sessions, down 4.90% for the selected period.

Last close
$30.10
Period change
-4.90%
Period low
$27.53
Period high
$32.59
Daily close
View OHLC price history
CLDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$29.70$30.27$29.20$30.10870.78K
Oct 29, 2026$29.79$30.385$29.465$29.89918.87K
Oct 28, 2026$29.63$30.015$28.92$29.66899.16K
Oct 27, 2026$29.50$30.395$29.33$30.15746.58K
Oct 26, 2026$29.37$29.90$28.985$29.50593.37K
Oct 23, 2026$28.95$29.38$28.20$29.25879.73K
Oct 22, 2026$29.08$29.725$28.49$28.97877.93K
Oct 21, 2026$30.29$30.72$29.31$29.371.12M
Oct 20, 2026$29.99$30.82$29.605$30.291.1M
Oct 19, 2026$27.73$29.845$27.50$29.671.72M
Oct 16, 2026$28.89$28.89$27.465$27.53997.97K
Oct 15, 2026$28.05$28.95$27.65$28.931.18M
Oct 14, 2026$28.49$28.73$27.68$27.8351.04M
Oct 13, 2026$29.28$29.28$27.92$28.251.9M
Oct 12, 2026$29.61$30.025$28.99$29.43596.42K
Oct 9, 2026$29.04$30.255$28.88$29.89992.78K
Oct 8, 2026$30.07$30.10$28.6251$29.303.95M
Oct 7, 2026$30.62$31.35$30.105$30.431.75M
Oct 6, 2026$32.68$32.68$30.85$31.0051.77M
Oct 5, 2026$31.83$32.88$31.50$32.591.26M
Oct 2, 2026$32.26$32.54$30.98$31.652.41M

Latest CLDX news

The latest Smart Investors Daily articles mentioning CLDX.

Stock researchCompany · Overview

CLDX research

Overview

Company profile and research snapshot.

Company profile

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$21.00
Implied upside
—
Analysts
—
CLDX recent ratings
DateFirmRatingTarget
Oct 2, 2026HC Wainwright & Co.Buy—
Sep 23, 2026Leerink PartnersOutperform—
Sep 23, 2026Morgan StanleyOverweight—
Sep 22, 2026Cantor FitzgeraldOverweight—
Sep 22, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 17, 2026

Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation

Celldex Therapeutics has seen a mixed share price story in recent years, and that uneven record puts the spotlight on whether the current market value still lines up with what its balance sheet supports. With fresh shareholder litigation headlines now in the mix, the question for you is how much of today’s price rests on expectations that sit beyond the company’s book value. Over the past 5 years the stock has fallen 41.9%, which puts long term holders squarely on the issue of whether the...

Yahoo · Sep 23, 2026

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

When biopharmaceutical companies advance platform technologies targeting complex immunological pathways, market participants must weigh clinical efficacy against the heavy capital requirements of drug development. Celldex Therapeutics (NASDAQ:CLDX) embodies the classic profile of a clinical-stage innovator: a proprietary mast cell inhibitor platform, a robust balance sheet insulated by substantial cash reserves, and multi-indication optionality across severe […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By